Sein Néoadjuvant FIGARO Feasibility and Accuracy of Lymph-node (LN) Restaging by Sentinel LN Procedure and Axillary LN Dissection in Ipsilateral Invasive Breast Cancer Relapse Saint-Cloud
Sarcomes STRASS 2 - ETUDE 1809-STBSG A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2) Paris SYLVIE BONVALOT
Prostate TEMPOS (GETUG P14) Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy Paris, Saint-Cloud
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Sein Néoadjuvant EMBER-2 (J2J-MC-JZLB) EMBER-2: A Phase 1, Open-Label, Preoperative Window Study Evaluating the Biological Effects of LY3484356 in Post-menopausal Women With Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Saint-Cloud FRANCOIS-CLEMENT BIDARD
Appareil Digestif PERSPECTIVE (MS202202-0002) A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE) Saint-Cloud
Prostate PRESTO (GETUG-AFU 36) Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial Paris
Sein Néoadjuvant NEOVAB Prospective Multicenter Pilot Study to Evaluate the Accuracy of Percutaneous Biopsy by Vacuum-assisted Biopsy (VAB) to Assess Pathological Complete Response in Patients With Clinical and Radiological Complete Response After Neoadjuvant Chemotherapy (NeoVAB) Saint-Cloud
Gynécologie - Ovaires MIRASOL MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression. Saint-Cloud